调节性T细胞体外诱导及其在器官移植中应用的研究进展

覃伟; 杨扬

doi:10.3969/j.issn.1674-7445.2014.05.014

调节性T细胞体外诱导及其在器官移植中应用的研究进展

doi: 10.3969/j.issn.1674-7445.2014.05.014

覃伟,
杨扬^,

510630 广州, 中山大学附属第三医院肝移植中心中山大学器官移植研究所广东省器官移植中心

基金项目:

国家自然科学基金 81370575

教育部博士点基金 20120171110082

第二军医大学东方肝胆外科医院国家科技重大专项合作 2012ZX10002010-001-007

详细信息

通讯作者:
杨扬,Email:yysysu@163.com

中图分类号: R617
计量
- 文章访问数: 65
- HTML全文浏览量: 9
- PDF下载量: 4
- 被引次数: 0
出版历程
- 收稿日期: 2014-05-16
- 刊出日期: 2014-09-15

摘要

摘要: 器官移植是目前国内外公认的治疗终末期疾病、挽救生命和提高生存质量的有效措施。移植后免疫排斥反应仍是器官移植的主要术后并发症,影响受者长期存活。虽然免疫抑制剂在临床应用中显示了良好的效果,但这些药物长期应用会使受者处于免疫低下状态,进而发生感染、肿瘤及其他并发症。
- 调节性T细胞 /
- 器官移植 /
- 免疫耐受 /
- 体外诱导

HTML全文

参考文献(33)

[1]	Sakaguchi S, Sakaguchi N, Asano M, et al. Pillars article: immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995[J].J Immunol,2011,186(7):3808-3821. http://cn.bing.com/academic/profile?id=2470754739&encoded=0&v=paper_preview&mkt=zh-cn
[2]	Ramsdell F. Foxp3 and natural regulatory T cells: key to a cell lineage?[J]. Immunity,2003,19(2):165-168. doi: 10.1016/S1074-7613(03)00207-3
[3]	马东霞,王璐,赵越, 等. OX40信号调节抑制小鼠CD4⁺ CD25⁺调节性T淋巴细胞Foxp3的表达[J].中华器官移植杂志,2013,34(7):424-427. Ma DX, Wang L, Zhao Y, et al. OX40 stimulation down-regulates the expression of Foxp3 in CD4⁺ CD25⁺ regulatory T cells[J]. Chin J Organ Transplant,2013,34(7):424-427.
[4]	Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function[J]. Nature,2007,450(7169):566-569. doi: 10.1038/nature06306
[5]	Shevach EM. Mechanisms of foxp3⁺ T regulatory cell-mediated suppression[J]. Immunity,2009,30(5):636-645. doi: 10.1016/j.immuni.2009.04.010
[6]	Tadokoro CE, Shakhar G, Shen S, et al. Regulatory T cells inhibit stable contacts between CD4⁺ T cells and dendritic cells in vivo[J]. J Exp Med,2006,203(3):505-511. doi: 10.1084/jem.20050783
[7]	Chou HS, Hsieh CC, Charles R, et al. Myeloid-derived suppressor cells protect islet transplants by B7-H1 mediated enhancement of T regulatory cells[J]. Transplantation,2012,93(3):272-282. doi: 10.1097/TP.0b013e31823ffd39
[8]	Chattopadhyay G, Shevach EM. Antigen-specific induced T regulatory cells impair dendritic cell function via an IL-10/MARCH1-dependent mechanism[J]. J Immunol,2013,191(12):5875-5884. doi: 10.4049/jimmunol.1301693
[9]	Earle KE, Tang Q, Zhou X, et al. In vitro expanded human CD4⁺ CD25⁺ regulatory T cells suppress effector T cell proliferation[J]. Clin Immunol,2005,115(1):3-9.
[10]	王永磊,朱志军. CD4⁺ CD25⁺调节性T细胞体内外培养扩增方法的研究进展[J].器官移植,2012,3(5):278-282. http://www.organtranspl.com/browse/detail/qkid/37/id/624.html Wang YL, Zhu ZJ. Progress of study on expansion of CD4⁺ CD25⁺T regulatory cells in vitro and in vivo culture[J]. Organ Transplant,2012,3(5):278-282. http://www.organtranspl.com/browse/detail/qkid/37/id/624.html
[11]	Hoffmann P, Eder R, Kunz-Schughart LA, et al. Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells[J]. Blood,2004,104(3):895-903. doi: 10.1182/blood-2004-01-0086
[12]	Wang J, Huizinga TW, Toes RE. De novo generation and enhanced suppression of human CD4⁺ CD25⁺ regulatory T cells by retinoic acid[J]. J Immunol,2009,183(6):4119-4126. doi: 10.4049/jimmunol.0901065
[13]	Zhang W, Zhang D, Shen M, et al. Combined administration of a mutant TGF-beta1/Fc and rapamycin promotes induction of regulatory T cells and islet allograft tolerance[J]. J Immunol,2010,185(8):4750-4759. doi: 10.4049/jimmunol.1000769
[14]	Hippen KL, Merkel SC, Schirm DK, et al. Massive ex vivo expansion of human natural regulatory T cells (Tregs) with minimal loss of in vivo functional activity[J]. Sci Transl Med,2011,3(83):83ra41. http://cn.bing.com/academic/profile?id=2145353379&encoded=0&v=paper_preview&mkt=zh-cn
[15]	Lu L, Ma J, Li Z, et al. All-trans retinoic acid promotes TGF-β-induced Tregs via histone modification but not DNA demethylation on Foxp3 gene locus[J]. PLoS One,2011,6(9):e24590. doi: 10.1371/journal.pone.0024590
[16]	Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4⁺ CD25⁺ Foxp3⁺ regulatory T lymphocytes[J]. Nat Med,2008,14(1):88-92. doi: 10.1038/nm1688
[17]	Feng G, Nadig SN, Bäckdahl L, et al. Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection[J]. Sci Transl Med,2011,3(83):83ra40. http://cn.bing.com/academic/profile?id=2157643208&encoded=0&v=paper_preview&mkt=zh-cn
[18]	Sagoo P, Ali N, Garg G, et al. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells[J]. Sci Transl Med,2011,3(83):83ra42. http://cn.bing.com/academic/profile?id=2018715802&encoded=0&v=paper_preview&mkt=zh-cn
[19]	Wright GP, Notley CA, Xue SA, et al. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis[J]. Proc Natl Acad Sci U S A,2009,106(45):19078-19083. doi: 10.1073/pnas.0907396106
[20]	Tsang JY, Tanriver Y, Jiang S, et al. Conferring indirect allospecificity on CD4⁺ CD25⁺ Tregs by TCR gene transfer favors transplantation tolerance in mice[J]. J Clin Invest,2008,118(11):3619-3628. doi: 10.1172/JCI33185
[21]	Peters JH, Hilbrands LB, Koenen HJ, et al. Ex vivo generation of human alloantigen-specific regulatory T cells from CD4(pos)CD25(high) T cells for immunotherapy[J]. PLoS One,2008,3(5):e2233. doi: 10.1371/journal.pone.0002233
[22]	Wang X, Lu L, Jiang S. Regulatory T cells: customizing for the clinic[J]. Sci Transl Med,2011,3(83):83ps19. http://cn.bing.com/academic/profile?id=2096286372&encoded=0&v=paper_preview&mkt=zh-cn
[23]	Cohen JL, Trenado A, Vasey D, et al. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease[J]. J Exp Med,2002,196(3):401-406. doi: 10.1084/jem.20020090
[24]	Hanash AM, Levy RB. Donor CD4⁺ CD25⁺ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation[J]. Blood,2005,105(4):1828-1836. doi: 10.1182/blood-2004-08-3213
[25]	Trzonkowski P, Bieniaszewska M, Juścińska J, et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4⁺ CD25⁺ CD127^- T regulatory cells[J]. Clin Immunol,2009,133(1):22-26. doi: 10.1016/j.clim.2009.06.001
[26]	Edinger M, Hoffmann P. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences[J]. Curr Opin Immunol,2011,23(5):679-684. doi: 10.1016/j.coi.2011.06.006
[27]	Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation[J].Blood,2011,117(14):3921-3928. doi: 10.1182/blood-2010-10-311894
[28]	Lu L, Blazar B, Li MY. Safety Study of Using Regulatory T Cells Induce Liver Transplantation Tolerance(Treg)[EB/OL]. (2013-08-01). http://clinicaltrials.gov/show/NCT01624077.
[29]	[European Commission. ONE Study[EB/OL]. (2013-08-04).www.onestudy.org.
[30]	Berglund D, Karlsson M, Biglarnia AR, et al. Obtaining regulatory T cells from uraemic patients awaiting kidney transplantation for use in clinical trials[J]. Clin Exp Immunol,2013,173(2):310-322. doi: 10.1111/cei.2013.173.issue-2
[31]	Sato Y, Chikako T, Oya H, et al. Regulatory T-cell activation among patients who displayed operational tolerance following intra-portal administration of donor-specific antigens in living donor liver transplantation[J]. Transplant Proc,2012,44(2):560-564. doi: 10.1016/j.transproceed.2012.01.045
[32]	Nguyen MT, Fryml E, Sahakian SK, et al. Pretransplantation recipient regulatory T cell suppressive function predicts delayed and slow graft function after kidney transplantation[J]. Transplantation,2014,DOI: 10.1097/TP.0000000000000219[Epub ahead of print].
[33]	Selin LK, Brehm MA, Naumov YN,et al. Memory of mice and men: CD8⁺ T-cell cross-reactivity and heterologous immunity[J]. Immunol Rev,2006,211: 164-181. doi: 10.1111/imr.2006.211.issue-1